Report of Foreign Issuer (6-k)
March 29 2017 - 9:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of March 2017
Commission File Number: 001-31995
MEDICURE
INC.
(Translation of registrant's name into English)
2-1250 Waverley Street
Winnipeg, MB Canada R3T 6C6
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant
by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes o
No x
If “Yes” is marked, indicate below
the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.
EXHIBIT
LIST
Exhibit |
Title |
|
|
99.1 |
News Release Dated March 29, 2017 - Medicure to Announce Fiscal Year End 2016 Financial Results on April 26, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Medicure Inc. |
|
(Registrant) |
|
|
|
|
|
Date: March 29, 2017 |
By: |
/s/ Dr. Albert D. Friesen |
|
Dr. Albert D. Friesen |
|
Title: President & CEO |
Exhibit 99.1
Medicure to Announce Fiscal Year End 2016 Financial Results
on April 26, 2017
WINNIPEG, March 29, 2017 /CNW/ - Medicure Inc. ("Medicure")
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will release financial results for the year ended December 31, 2016
after market close on Wednesday, April 26, 2017. The results are being released later than the previous fiscal year's results as
the financial statements will include the operations and balances of Apicore from the acquisition date of December 1, 2016.
This release and filing date meets TSX Venture Exchange listed company requirements. Medicure will hold a conference call and webcast
regarding the results on Thursday, April 27, 2017 at 7:30 AM Central Time (8:30 AM Eastern Time).
Conference Call Info:
Topic: Medicure's Fiscal Year End 2016 Results
Call date: Thursday, April 27, 2017
Time: 7:30 AM Central Time (8:30 AM Eastern Time)
Canada toll-free: 1 (888) 465-5079 Canada
toll: 1 (416) 216-4169
United States toll-free: 1 (888) 545-0687
Passcode: 9165 999#
Webcast: This conference call will be webcast live over
the internet and can be accessed from the Medicure investor relations page at the following link: http://www.medicure.com/investors.html
You may request international country-specific access information
by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations
during the question-and-answer period at the end of the conference call. A recording of the call will be available following the
event at the Company's website.
About Medicure Inc.
Medicure is a specialty pharmaceutical company focused on
the development and commercialization of therapeutics for the U.S. hospital market. The primary focus of the Company and its subsidiaries
is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) in the United States, where it is sold through the Company's
U.S. subsidiary, Medicure Pharma, Inc. For more information on Medicure please visit www.medicure.com.
About Apicore
Apicore is a private, New Jersey based developer and manufacturer
of specialty Active Pharmaceutical Ingredients ("APIs") and pharmaceuticals, including over 15 Abbreviated New Drug Applications
("ANDAs"), one of which, is partnered with Medicure. Apicore manufactures over 100 different API's, including over
35 for which Drug Master Files have been submitted to the FDA and 16 that are approved for commercial sale in the U.S. by customers
of Apicore. Apicore specializes in the manufacture of difficult to synthesize, high value and other niche API's for many
U.S. and international generic and branded pharmaceutical companies. Apicore has two FDA-approved facilities. In the U.S.,
the Somerset, New Jersey facility can produce a few grams up to 200 kg volumes and in India, the Vadodara, Gujarat facility can
produce a few kilograms up to 60 metric tons yearly. Both facilities are equipped with state-of-the-art analytical and research
capabilities. For more information, please visit Apicore online at www.apicore.com.
To be added to Medicure's e-mail list, please visit: http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy
of this release.
SOURCE Medicure Inc.
To view the original version on PR Newswire, visit: http://www.newswire.ca/en/releases/archive/March2017/29/c4495.html
%CIK: 0001133519
For further information: James Kinley, Chief Financial Officer,
Tel. 888-435-2220, Fax 204-488-9823, E-mail: info@medicure.com, www.medicure.com
CO: Medicure Inc.
CNW 09:00e 29-MAR-17
This regulatory filing also includes additional resources:
ex991.pdf
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Sep 2023 to Sep 2024